Search the Newsreel

Corteva files amendment for Vylor spin-off registration statement

Corteva, Inc. announced that its subsidiary, Vylor, Inc., has filed the first amendment to its Form 10 registration statement with the SEC, moving forward with the plan to spin off its seed business into an independent, publicly traded company. The filing details Vylor's operations …

Corteva files amendment for Vylor seed business spin-off with SEC

Corteva, Inc. announced that its subsidiary, Vylor, Inc., has filed an amendment to its Form 10 registration statement with the SEC, detailing Vylor’s business operations, strategy, and historical financial results. This filing is a step towards spinning off Corteva's seed business into an independent, …

Form 8K Corteva Inc For: 14 August By Investing.com

This article announces that Corteva Inc. filed a Form 8K on August 14. It briefly mentions the company's stock symbol CTVA and its stock performance. The article is a concise notification about the filing.

Corcept Therapeutics (CORT) CBO reports 17,530-share stock gifts and trust holdings

Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, reported several bona fide gift transactions involving 17,530 shares of the company's common stock on August 12, 2026. These transactions included a direct gift disposition of 11,530 shares and gifts of 3,000 shares each to two …

Corteva Inc. stock outperforms competitors on strong trading day

Corteva Inc. (CTVA) shares rose by 1.17% to $76.68 on Friday, despite a generally negative trading day for the broader market, with both the S&P 500 and Dow Jones Industrial Average experiencing declines. This marked the second consecutive day of gains for Corteva's stock, …

Notable ETF Outflow Detected - SPSM, CORT, GKOS, EAT

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio S&P 600 Small Cap ETF (Symbol: SPSM) where we have detected an approximate $125.1 million dollar outflow -- that's a 0.7% decrease …

Renaissance Technologies (CORT) discloses 4.90% beneficial stake in Corcept Therapeutics

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a beneficial ownership of 4.90% in Corcept Therapeutics Inc., amounting to 5,261,628 shares of common stock. This Schedule 13G/A filing indicates that Renaissance Technologies holds sole voting and dispositive power over these shares. Certain …

Judge in Inari-Corteva Suit Wants Answers About Sponsored Ad

A Delaware judge has ordered agricultural company Inari to explain how a sponsored online advertisement, which appeared ahead of a patent trial against Corteva Agriscience LLC, complies with professional conduct rules. The judge is questioning whether the ad, titled "The Facts on Seed Litigation," …

Corteva (NYSE:CTVA) Stock Rating Lowered by Zacks Research

Zacks Research downgraded Corteva (NYSE:CTVA) from a "strong-buy" to a "hold" rating, though the overall analyst consensus remains a "Moderate Buy" with a $91.70 target price. Despite exceeding EPS expectations with $2.30 against a forecast of $2.24, Corteva's revenue of $6.38 billion missed estimates …

Corcept chief development officer sells $418,561 of stock

Corcept Therapeutics Inc.'s Chief Development Officer, William Guyer, sold 3,700 shares of the company's stock for $418,561, while simultaneously acquiring the same number of shares through stock options for $80,105. This transaction comes as Corcept's stock has seen significant gains, trading near its 52-week …

Capital World Investors (NYSE: CTVA) reports 6.6% ownership stake in Corteva

Capital World Investors has reported a 6.6% ownership stake in Corteva, Inc., totaling 43,841,218 shares of common stock. This beneficial ownership includes sole voting power over 43,417,923 shares and sole dispositive power over all 43,841,218 shares. The filing indicates this stake is held across …

Sean Maduck Sells 1,031 Shares of Corcept Therapeutics (NASDAQ:CORT) Stock

Sean Maduck, an insider at Corcept Therapeutics (NASDAQ:CORT), sold 1,031 shares of the company's stock on August 10th, valued at approximately $118,070, reducing his holdings by 9.56%. This sale is part of a series of transactions by Maduck in recent months. The company recently …

Corteva's Higher 2026 Guidance Puts Investor Focus on Growth Drivers

Corteva, Inc. CTVA delivered a mixed second-quarter 2026 performance, with earnings exceeding expectations while revenues fell short of the Zacks Consensus Estimate. The company raised its full-year outlook, supported by Seed technology demand, productivity initiatives and new Crop Protection products. However, investors must weigh …

Corteva Growth Improves, But Valuation Limits Upside

Corteva, Inc. CTVA is showing improving earnings momentum as technology adoption, productivity actions and a stronger Seed business support growth. However, the stock's valuation and ongoing Crop Protection pricing pressures keep the risk-reward balance more measured. The stock currently carries a Zacks Rank #3 …

Corteva, Inc. $CTVA Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB significantly reduced its stake in Corteva, Inc. by 13.3% in the second quarter, selling 53,264 shares and now owning 347,071 shares valued at $29.39 million. Despite this, other institutional investors have recently acquired new stakes or increased their holdings in Corteva. …

Sei Investments Co. Sells 62,377 Shares of Corcept Therapeutics Incorporated $CORT

Sei Investments Co. reduced its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 65.8% in the first quarter, selling 62,377 shares. Other institutional investors, including First Trust Advisors LP, AQR Capital Management LLC, and Geode Capital Management LLC, either increased their positions or bought new …

Amundi Acquires New Shares in Corcept Therapeutics Incorporated $CORT

Amundi acquired 11,392 shares of Corcept Therapeutics (CORT) in the first quarter, valued at $459,000, adding to the 93.61% institutional ownership of the company. Despite significant insider selling totaling $33.15 million over the past 90 days, Corcept reported strong quarterly earnings of $0.36 EPS, …

Upgraded 2026 Revenue Outlook And Buybacks Might Change The Case For Investing In Corcept (CORT)

Corcept Therapeutics reported increased net income in Q2 2026 and raised its full-year 2026 revenue guidance to US$1.10–1.20 billion, along with completing a share repurchase program. This updated outlook, driven by confidence in its cortisol-modulation portfolio and new indications, signals a potential shift in …

Corteva Seed-Patent Suit Gets Trimmed Ahead of September Trial

A federal judge has limited the scope of an upcoming patent trial between Corteva Inc. and Inari Agriculture Inc., ruling that Inari cannot claim false advertising against Corteva. Inari had alleged false advertising based on a Corteva press release, but the court found no …

Corcept Therapeutics Incorporat (CORT) Stock Forecasts

Argus has raised its target price for Corcept Therapeutics Inc (CORT) to $115.00, noting the company's focus on developing medications for severe metabolic, oncologic, and neuropsychiatric disorders. The current price for CORT is $111.86. The report emphasizes the company's commercial-stage pharmaceutical operations.

Assenagon Asset Management S.A. Cuts Stock Position in Corteva, Inc. $CTVA

Assenagon Asset Management S.A. significantly reduced its stake in Corteva, Inc. by 65% in the second quarter, selling 324,734 shares and retaining 174,783 shares valued at approximately $14.8 million. Despite mixed financial results with EPS beating estimates but revenue falling short, Corteva maintained its …

Corteva Inc (CTVA) Stock News Today

This article provides recent news and analysis for Corteva Inc (CTVA) stock. It highlights a 10.51% stock price movement down on July 31st and includes links to other relevant stock news, such as Linde PLC. The page also provides current stock data for Corteva, …

Are Wall Street Analysts Bullish on Corteva Stock?

Corteva office in Wilmington By JHVEPhoto With a market cap of $51.3 billion, Corteva, Inc. (CTVA) is a global pure-play agriculture company providing innovative seed, crop protection, and digital solutions to address the world's most pressing agricultural challenges. Through its strong brands, advanced technology …

Corcept Therapeutics (CORT) Stock Report: A Potential 22% Upside Amid Robust Revenue Growth

How Corteva Inc. (CTVA) Affects Rotational Strategy Timing

Corteva Inc. (CTVA) is showing weak near and mid-term sentiment, posing a challenge to its long-term positive outlook. The analysis highlights an elevated downside risk with no additional long-term support signals remaining. Institutional trading strategies, including position, momentum breakout, and risk hedging, have been …

Projeções de Resultados: Corteva Inc (CTVA) — LPA e Crescimento de Receita

PensionDanmark Pensionsforsikringsaktieselskab Sells 35,576 Shares of Corteva, Inc. $CTVA

PensionDanmark Pensionsforsikringsaktieselskab significantly reduced its stake in Corteva, Inc. by selling 35,576 shares, bringing its total holdings to 146,962 shares valued at approximately $12.45 million. Despite this sale, institutional investors collectively own 81.54% of Corteva. The company reported strong quarterly EPS, beating estimates, and …

12,478 Shares in Corcept Therapeutics Incorporated $CORT Purchased by Evanson Financial LLC

Evanson Financial LLC recently acquired 12,478 shares of Corcept Therapeutics (NASDAQ:CORT) worth approximately $1.085 million. This purchase is part of broader institutional investor activity, with hedge funds owning 93.61% of the company's stock. Despite some analyst downgrades and insider selling, the company recently beat …

Enterprise value to EBITDA forward of Corteva Inc – MUN:2X0

This page provides financial information for Corteva Inc (MUN:2X0), specifically focusing on its enterprise value to EBITDA forward. It indicates that the market for this stock is currently closed with no trades. The content is primarily a financial data point with surrounding navigation and …

Corcept Therapeutics (CORT) Lifted Guidance, Is The Upside Already Priced In?

Corcept Therapeutics (CORT) is gaining attention after its Q2 earnings report, which included increased full-year 2026 revenue guidance and a share buyback update. While the stock has shown significant positive momentum over the long term, Simply Wall St's analysis suggests it is currently 23% …

Corcept Therapeutics (CORT) Stock May Trade At A Discount Yet A Premium On Sales

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Corcept Therapeutics stock has delivered a very strong run over the past few years, yet its low overall value score suggests the current share …

Corteva Inc (CTVA) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Corteva Inc (CTVA), noting its current earnings forecast score of 7.74, ranking 24th in the Chemicals industry. Analysts have set an average price target of $78.00, with a majority recommending a "Buy" rating. The company's expected revenue …

Insider Selling: Corcept Therapeutics (NASDAQ:CORT) Insider Sells 3,700 Shares

Corcept Therapeutics insider William Guyer sold 3,700 shares of the company's stock for $418,544 on August 4th, reducing his ownership by 48.15%. This sale follows previous transactions in June and July. Despite the insider selling, Corcept Therapeutics reported strong quarterly earnings, beating consensus estimates …